|
SI1859798T1
(sl)
*
|
2001-03-29 |
2016-07-29 |
Eli Lilly And Company |
N-(2-ariletil) benzil amini kot antagonisti 5-ht6 receptorja
|
|
EP1411925A1
(en)
*
|
2001-08-03 |
2004-04-28 |
PHARMACIA & UPJOHN COMPANY |
5-arylsulfonyl indoles having 5-ht6 receptor affinity
|
|
AU2003249582B2
(en)
|
2002-06-21 |
2006-08-03 |
Suven Life Sciences Limited |
Tetracyclic arylsulfonyl indoles having serotonin receptor affinity
|
|
JP4567448B2
(ja)
*
|
2002-07-17 |
2010-10-20 |
レツク・フアーマシユーテイカルズ・デー・デー |
コレステロール生合成の阻害剤としての新規なピリジルエタノール（フェニルエチル）アミン誘導体、その調製方法、および新規な誘導体を含有する医薬組成物
|
|
MY140236A
(en)
|
2002-09-19 |
2009-12-31 |
Lilly Co Eli |
Diarylether compounds useful as opioid receptor antagonists
|
|
CN1729174B
(zh)
*
|
2002-12-20 |
2015-10-21 |
西巴特殊化学品控股有限公司 |
胺的合成以及用于合成胺的中间体
|
|
ATE406360T1
(de)
|
2003-03-07 |
2008-09-15 |
Lilly Co Eli |
Antagonisten der opioidrezeptoren
|
|
BRPI0407616A
(pt)
|
2003-03-07 |
2006-02-14 |
Lilly Co Eli |
composto, composição farmacêutica, método para bloquear uma combinação de receptor de mu, capa, delta (heterodìmero) deste em mamìferos, método para tratar ou prevenir obesidade e doenças relacionadas, uso de um composto, e método de suprimir o apetite em um paciente em necessidade deste"
|
|
DE10320782A1
(de)
*
|
2003-05-09 |
2004-11-25 |
Bayer Cropscience Ag |
Substituierte Oxyarene
|
|
EP1558582B1
(en)
|
2003-07-22 |
2005-12-21 |
Arena Pharmaceuticals, Inc. |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
|
|
AU2004312312A1
(en)
|
2003-12-22 |
2005-07-21 |
Eli Lilly And Company |
Opioid receptor antagonists
|
|
CA2558568A1
(en)
|
2004-03-12 |
2005-09-29 |
Eli Lilly And Company |
Opioid receptor antagonists
|
|
WO2005092836A1
(en)
|
2004-03-15 |
2005-10-06 |
Eli Lilly And Company |
Opioid receptor antagonists
|
|
DE602005012380D1
(de)
|
2004-03-15 |
2009-03-05 |
Lilly Co Eli |
4-(5-(aminomethyl)-indol-1-ylmethyl)benzamidderivate und verwandte verbindungen als opioidrezeptorantagonisten zur behandlung von fettleibigkeit
|
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
|
CN101891680B
(zh)
|
2004-06-24 |
2014-10-29 |
沃泰克斯药物股份有限公司 |
Atp-结合弹夹转运蛋白的调控剂
|
|
EP1632491A1
(en)
*
|
2004-08-30 |
2006-03-08 |
Laboratorios Del Dr. Esteve, S.A. |
Substituted indole compounds and their use as 5-HT6 receptor modulators
|
|
SI1809622T1
(sl)
*
|
2004-09-22 |
2010-11-30 |
Janssen Pharmaceutica Nv |
Inhibitorji interakcije med MDM in P
|
|
US7459469B2
(en)
|
2004-11-10 |
2008-12-02 |
Targacept, Inc. |
Hydroxybenzoate salts of metanicotine compounds
|
|
DE102004062542A1
(de)
*
|
2004-12-24 |
2006-07-06 |
Bayer Cropscience Ag |
Substituierte Oxyarene
|
|
JP5170742B2
(ja)
*
|
2005-12-28 |
2013-03-27 |
積水メディカル株式会社 |
凝集測定用試薬及び凝集測定方法
|
|
DK3219705T3
(da)
|
2005-12-28 |
2020-04-14 |
Vertex Pharma |
Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
|
|
CN101400677A
(zh)
*
|
2006-01-06 |
2009-04-01 |
阿斯利康(瑞典)有限公司 |
化合物
|
|
ATE470665T1
(de)
|
2006-03-22 |
2010-06-15 |
Janssen Pharmaceutica Nv |
Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53
|
|
US8232298B2
(en)
|
2006-03-22 |
2012-07-31 |
Janssen Pharmaceutica N.V. |
Inhibitors of the interaction between MDM2 and P53
|
|
EP2021325A2
(en)
|
2006-05-09 |
2009-02-11 |
AstraZeneca AB |
Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
|
|
TWI389889B
(zh)
|
2006-05-09 |
2013-03-21 |
Targacept Inc |
（２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
|
|
EP1953153A1
(en)
*
|
2007-01-31 |
2008-08-06 |
Laboratorios del Dr. Esteve S.A. |
Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
|
|
ES2534899T3
(es)
|
2007-08-06 |
2015-04-30 |
Janssen Pharmaceutica, N.V. |
Fenilendiaminas sustituidas como inhibidores de la interacción entre MDM2 y p53
|
|
JO2704B1
(en)
|
2007-09-21 |
2013-03-03 |
جانسين فارماسوتيكا ان في |
Interference inhibition factors between MD2 and B53
|
|
WO2009049030A1
(en)
*
|
2007-10-09 |
2009-04-16 |
Triton Biopharma, Llc |
Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter
|
|
EP2231160B1
(en)
*
|
2007-12-04 |
2013-08-14 |
Merck Sharp & Dohme Corp. |
Tryptamine sulfonamides as 5-ht6 antagonists
|
|
EP2254564A1
(en)
|
2007-12-12 |
2010-12-01 |
Glaxo Group Limited |
Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
|
|
EP2254865A1
(en)
*
|
2008-02-11 |
2010-12-01 |
Organix, Inc. |
Indole compounds and methods of use thereof
|
|
US20110021538A1
(en)
|
2008-04-02 |
2011-01-27 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
|
US12458635B2
(en)
|
2008-08-13 |
2025-11-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
|
WO2010062321A1
(en)
|
2008-10-28 |
2010-06-03 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
|
|
MX2011008195A
(es)
*
|
2009-02-04 |
2011-09-06 |
Janssen Pharmaceutica Nv |
Derivados de indol como agentes anticancer.
|
|
JP5083256B2
(ja)
*
|
2009-03-20 |
2012-11-28 |
株式会社デンソー |
半導体装置およびその製造方法
|
|
KR101727762B1
(ko)
|
2009-03-20 |
2017-04-17 |
버텍스 파마슈티칼스 인코포레이티드 |
낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
|
|
US8912220B2
(en)
|
2009-08-10 |
2014-12-16 |
Galenea Pharmaceuticals |
Compounds and methods of use thereof
|
|
EP2311823A1
(en)
|
2009-10-15 |
2011-04-20 |
AC Immune S.A. |
2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
|
|
TW201139370A
(en)
*
|
2009-12-23 |
2011-11-16 |
Lundbeck & Co As H |
Processes for the manufacture of a pharmaceutically active agent
|
|
FR2961095B1
(fr)
*
|
2010-06-09 |
2012-06-15 |
Oreal |
Composition cosmetique et/ou dermatologique comprenant au moins un compose 6-alcoxy tryptamine
|
|
FR2961097B1
(fr)
*
|
2010-06-09 |
2012-07-13 |
Oreal |
Procede cosmetique de traitement des odeurs corporelles humaines utilisant un compose 6-alkoxy tryptamine
|
|
US8293218B2
(en)
*
|
2010-07-29 |
2012-10-23 |
Conopco, Inc. |
Skin care compositions comprising substituted monoamines
|
|
US8802700B2
(en)
|
2010-12-10 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
JP2015511583A
(ja)
|
2012-02-27 |
2015-04-20 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
薬学的組成物およびその投与
|
|
AU2013237020B2
(en)
|
2012-03-20 |
2016-10-06 |
Adamed Sp. Z O.O. |
Sulphonamide derivatives of benzylamine for the treatment of CNS diseases
|
|
CN102746211B
(zh)
*
|
2012-06-27 |
2015-05-27 |
上海泰坦化学有限公司 |
一种取代吲哚-3-甲醛类化合物的制备方法
|
|
JO3459B1
(ar)
|
2012-09-09 |
2020-07-05 |
H Lundbeck As |
تركيبات صيدلانية لعلاج مرض الزهايمر
|
|
WO2014078568A1
(en)
|
2012-11-14 |
2014-05-22 |
The Johns Hopkins University |
Methods and compositions for treating schizophrenia
|
|
US20160038484A1
(en)
*
|
2013-04-03 |
2016-02-11 |
The University Of Utah Research Foundation |
Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
|
|
CN104725249B
(zh)
*
|
2013-12-20 |
2019-02-12 |
广东东阳光药业有限公司 |
苄胺类衍生物及其在药物上的应用
|
|
JO3639B1
(ar)
*
|
2014-07-04 |
2020-08-27 |
H Lundbeck As |
صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
|
|
CN107250113B
(zh)
|
2014-10-07 |
2019-03-29 |
弗特克斯药品有限公司 |
囊性纤维化跨膜传导调节蛋白的调节剂的共晶
|
|
ES2570452B1
(es)
*
|
2014-10-15 |
2017-04-19 |
Fundación Para La Investigación Biomédida Del Hospital Universitario De La Princesa |
Compuestos derivados de acrilato de 3-Alquilamino-1H-Indolilo y su uso en el tratamiento de enfermedades neurodegenerativas
|
|
CN105175307A
(zh)
*
|
2014-11-18 |
2015-12-23 |
苏州晶云药物科技有限公司 |
Lu AE58054的盐酸盐晶型A及其制备方法和用途
|
|
CN104529865B
(zh)
*
|
2014-12-12 |
2017-02-01 |
广东东阳光药业有限公司 |
苄胺类衍生物及其在药物上的应用
|
|
TW201630881A
(zh)
|
2014-12-12 |
2016-09-01 |
Ｈ 朗德貝克公司 |
用於生產艾達魯吡啶之方法
|
|
HK1245660A1
(zh)
|
2015-06-12 |
2018-08-31 |
Axovant Sciences Gmbh |
有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物
|
|
WO2017011767A2
(en)
|
2015-07-15 |
2017-01-19 |
Axovant Sciences Ltd. |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
|
|
CN108271369A
(zh)
|
2015-10-23 |
2018-07-10 |
法尔玛赞公司 |
用于制备色胺及其衍生物的新工艺
|
|
US9975850B2
(en)
|
2016-04-08 |
2018-05-22 |
H. Lundbeck A/S |
Process for the manufacture of idalopirdine via hydrogenation of an imine
|
|
PT3448430T
(pt)
*
|
2016-04-26 |
2023-07-11 |
H Lundbeck As |
Uso de inibidores da acetilcolinesterase e idalopirdina para reduzir quedas em doentes com doença de parkinson
|
|
US10864191B2
(en)
|
2016-05-11 |
2020-12-15 |
H. Lundbeck A/S |
5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
|
|
WO2018013686A1
(en)
*
|
2016-07-12 |
2018-01-18 |
Concert Pharmaceuticals, Inc. |
Deuterated idalopirdine
|
|
EP3333154A1
(en)
|
2016-12-07 |
2018-06-13 |
Sandoz Ag |
Crystalline form of a selective 5-ht6 receptor antagonist
|
|
CN106632303A
(zh)
*
|
2017-01-09 |
2017-05-10 |
湖南华腾制药有限公司 |
一种6‑噻唑基吲哚衍生物的制备方法
|
|
WO2018191146A1
(en)
*
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
|
HUE053636T2
(hu)
|
2017-05-24 |
2021-07-28 |
H Lundbeck As |
5-HT6 receptor antagonista és acetilkolin-észteráz inhibitor kombinációja Alzheimer-kór kezelésében történõ alkalmazásra ApoE4 alléleket hordozó betegek szubpopulációjában
|
|
CA3185336A1
(en)
|
2017-11-06 |
2019-05-09 |
Acelot, Inc. |
Small molecule drugs and related methods for treatment of diseases related to a.beta.42 oligomer formation
|
|
KR20210135521A
(ko)
|
2019-03-06 |
2021-11-15 |
다이이찌 산쿄 가부시키가이샤 |
피롤로피라졸 유도체
|
|
CN109942527A
(zh)
*
|
2019-04-26 |
2019-06-28 |
新乡市润宇新材料科技有限公司 |
一种3-溴二苯并呋喃的合成方法
|
|
EP4146198A4
(en)
|
2020-05-08 |
2024-05-15 |
Psilera Inc. |
Novel compositions of matter and pharmaceutical compositions
|
|
US12240813B2
(en)
|
2020-05-19 |
2025-03-04 |
Cybin Irl Limited |
Deuterated tryptamine derivatives and methods of use
|
|
IL301028A
(en)
*
|
2020-09-02 |
2023-05-01 |
Enveric Biosciences Canada Inc |
Nitrated psilocybin derivatives and use thereof for modulating 5-ht2a receptor and for treating a psychiatric disorder
|
|
US12559491B2
(en)
*
|
2020-09-17 |
2026-02-24 |
Merck Sharp & Dohme Llc |
Modified imidazopyridines as glucosylceramide synthase inhibitors
|
|
IL305125A
(en)
*
|
2021-02-12 |
2023-10-01 |
Enveric Biosciences Canada Inc |
Multi-substituent psilocybin derivatives and methods of using
|
|
KR20230154219A
(ko)
*
|
2021-03-02 |
2023-11-07 |
마인드셋 파마 인크. |
세로토닌성 작용제와 관련된 장애의 치료에 유용한 세로토닌성 작용제로서의 인돌 유도체
|
|
US20240254087A1
(en)
*
|
2021-05-11 |
2024-08-01 |
Saint Joseph's University |
Selective, partial, and arrestin-biased 5-ht2a agonists with utility in various disorders
|
|
CA3218110A1
(en)
|
2021-05-25 |
2022-12-01 |
Majed Fawaz |
New n,n-dimethyltryptamine salts and crystalline salt forms
|
|
BR112023025599A2
(pt)
|
2021-06-08 |
2024-02-20 |
Entheogenix Biosciences Inc |
Ativadores de dimetoxifenilalquilamina de receptores de serotonina.
|
|
US20230041584A1
(en)
|
2021-06-09 |
2023-02-09 |
ATAI Life Sciences AG |
Novel prodrugs and conjugates of dimethyltryptamine
|
|
WO2023044577A1
(en)
*
|
2021-09-24 |
2023-03-30 |
Psygen Inc. |
Recovery method for tryptamines
|
|
JP2024547131A
(ja)
|
2021-12-27 |
2024-12-26 |
エーティーエーアイ セラピューティクス，インコーポレイテッド |
セロトニン受容体のアミノテトラリン活性化剤
|
|
EP4457214A4
(en)
|
2021-12-30 |
2025-12-03 |
Atai Therapeutics Inc |
DIMETHYLTRYPTAMINE ANALOGUES USED AS NITRIC OXIDE ADMINISTRATION MEDICINES
|
|
WO2023173196A1
(en)
|
2022-03-18 |
2023-09-21 |
Enveric Biosciences Canada Inc. |
C4-carboxylic acid-substituted tryptamine derivatives and methods of using
|
|
EP4704822A1
(en)
|
2023-05-01 |
2026-03-11 |
ATAI Therapeutics, Inc. |
Compositions and methods for treatment of diseases and disorders
|
|
WO2025160304A1
(en)
*
|
2024-01-24 |
2025-07-31 |
Automera PTE. LTD |
Indole derivatives for targeting autophagy
|